Cypher withdrawal issues resolved, says Johnson & Johnson
This article was originally published in Clinica
Johnson & Johnson had already corrected by January 14 the manufacturing process that led to its voluntary withdrawal of 300 drug-eluting Cypher stents on January 13, a spokesperson for the company's Cordis business told Clinica. The single lot of devices was called back from 145 hospital accounts after six coronary stents were found during manufacturing auditing at a Puerto Rico production facility to have a reduced amount of polymer coating. The problem was immediately identified and corrective steps were taken, said the company.